SciClone to Restate Financial Statements

SciClone Pharmaceuticals (NASDAQ: SCLN  ) is to restate a set of its financial statements from 2011 and 2012 due to what it says are accounting errors within its subsidiary NovaMed regarding certain line items and timing. The company expects the restatement to lift the revenue and earnings of 2012, and decrease both for 2011.

The affected periods are each of the first three quarters of last year, as well as Q2, Q3, and full-year 2011.

SciClone quoted CEO Friedhelm Blobel as saying that the decision to restate "was made after careful review of all the available facts, the applicable technical accounting rules regarding revenue recognition, and with the full cooperation and input of our independent registered public accounting firm."

The company said it aims to correct the irregularities "as soon as reasonably practicable."

link


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2276363, ~/Articles/ArticleHandler.aspx, 10/31/2014 1:08:01 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement